Virtual Panel: Digitization of Clinical Trials

Sponsored by: Microsoft

Matt O’Donnell, Microsoft Life Sciences Industry Executive
Tom Arneman, EPAM Strategy & Business Development Lead
Bill Byrom, Signant Health VP of Product Intelligence & Positioning

Tuesday - May 18, 2021 / 1:00pm ET
Free Event

Register now

Advancements in technology are impacting clinical trials and accelerating the speed and quality of new therapies being brought to market.  To date, the adoption of digital elements has largely been through small incremental changes over time. But as we have seen across the Healthcare and Life Sciences industries, COVID-19 has accelerated the need for change for clinical trial process.  In the last year, more virtual and digital aspects became a necessity for some trials to continue.  Fortunately, this transformation has delivered some clear benefits for Pharmaceutical companies and entire patient populations.  But these advancements did not occur without challenges and risks that needed to be carefully considered and mitigated.

The panel will evaluate various aspects of a clinical trial ‘digital twin’ – where a digital representation of every physical aspect exists – and provide perspectives on the benefits, challenges, and design considerations. Join us to learn more about:

  • Details of clinical trial ‘digital twins’
  • Benefits / Challenges / Risks
  • Design considerations considering current technology and limitations

This virtual panel will be moderated by Taren Grom, Co-Founder and Editor-in-Chief of PharmaVOICE.


About the Sponsors

At Microsoft, we empower healthcare and life science organizations of all sizes to reimagine the ways they bring together people, processes, and health data insights to improve care delivery. Microsoft Cloud for Healthcare brings together trusted capabilities to customers and partners that enhances patient engagement, empowers team collaboration, and improves clinical and operational insights. It helps customers support their end-to-end security, compliance, and interoperability of data needs.

For more information please visit

Comments are closed.